Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant <it>Escherichia coli </it>in ICU: A retrospective study

Incidence and impact on clinical outcome of infections with piperacillin/tazobactam resistant <it>Escherichia coli </it>in ICU: A retrospective study

<p>Abstract</p> <p>Background</p> <p><it>Escherichia coli </it>infections are frequent in ICU patients. The increased resistance to fluoroquinolones and amoxicillin/clavulanate of this pathogen mandates the prescription of broad-spectrum antibiotics such as...

Full description

Bibliographic Details
Main Authors:	Mounier Roman, Chevrel Guillaume, Eveillard Mathieu, Barnaud Guilène, Ricard Jean-Damien, Meybeck Agnès, Dreyfuss Didier
Format:	Article
Language:	English
Published:	BMC 2008-05-01
Series:	BMC Infectious Diseases
Online Access:	http://www.biomedcentral.com/1471-2334/8/67

Similar Items

Piperacillin–tazobactam as alternative to carbapenems for ICU patients
by: Benoit Pilmis, et al.
Published: (2017-11-01)

Mechanisms of Piperacillin/Tazobactam Nephrotoxicity: Piperacillin/Tazobactam-Induced Direct Tubular Damage in Mice
by: Jihyun Yang, et al.
Published: (2023-06-01)

Ultrasensitive and rapid identification of ESRI developer- and piperacillin/tazobactam-resistant Escherichia coli by the MALDIpiptaz test
by: Angel Rodríguez Villodres, et al.
Published: (2022-12-01)

Piperacillin/tazobactam in modern clinical practice
by: Igor Bereznyakov
Published: (2022-05-01)

Comparison of risk of acute kidney injury between patients receiving the combination of teicoplanin and piperacillin/tazobactam versus vancomycin and piperacillin/tazobactam
by: Chi-Hao Shao, et al.
Published: (2022-01-01)

Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of blaTEM-1B.
by: Hubbard, ATM, et al.
Published: (2020)

Comparison of the Effectiveness of Piperacillin-Tazobactam and Carbapenems in Nosocomial Infections with Extended-Spectrum Beta-lactamase-Producing Escherichia coli and Klebsiella pneumoniae
by: Müge AYHAN, et al.
Published: (2020-12-01)

Piperacillin/tazobactam resistance in a clinical isolate of Escherichia coli due to IS26-mediated amplification of bla TEM-1B
by: Alasdair T. M. Hubbard, et al.
Published: (2020-10-01)

Piperacillin-Tazobactam (TZP) Resistance in Escherichia coli Due to Hyperproduction of TEM-1 β-Lactamase Mediated by the Promoter Pa/Pb
by: Kaixin Zhou, et al.
Published: (2019-04-01)

Topical piperacillin/tazobactam for recalcitrant pseudomonas aeruginosa keratitiS
by: Chew, F.L.M., et al.
Published: (2010)

Evaluation of Strategies for Reducing Vancomycin-Piperacillin/Tazobactam Incompatibility
by: Anthony Martin Mena, et al.
Published: (2023-08-01)

Piperacillin/Tazobactam-Induced Neutropenia: A Case Report
by: Hayati DEMİRASLAN, et al.
Published: (2012-03-01)

Piperacilina/tazobactam en el sistema VITEK ®2 Piperacillin / Tazobactam in the VITEk ®2 System
by: Javier Gutman, et al.
Published: (2011-06-01)

Piperacillin/tazobactam-resistant, cephalosporin-susceptible Escherichia coli bloodstream infections are driven by multiple acquisition of resistance across diverse sequence types
by: Edwards, T, et al.
Published: (2022)

Hematologic Adverse Effects of Prolonged Piperacillin- Tazobactam Use in Adults
by: Aysun Benli, et al.
Published: (2018-11-01)

<i>Enterobacter </i>endophthalmitis: Treatment with intravitreal tazobactam- piperacillin
by: Singh Trehan, et al.
Published: (2007-01-01)

Results of the effectiveness of two piperacillin–tazobactam molecules in the real world
by: Jorge Enrique Machado-Alba, et al.
Published: (2018-11-01)

Extensive Gene Amplification as a Mechanism for Piperacillin-Tazobactam Resistance in <named-content content-type="genus-species">Escherichia coli</named-content>
by: Lisa M. Schechter, et al.
Published: (2018-05-01)

Impact of extended-infusion piperacillin-tazobactam in a Canadian community hospital
by: April J. Chan, et al.
Published: (2023-03-01)

Incidence and Determinants of Piperacillin/Tazobactam-Associated Hypokalemia: A Retrospective Study
by: Heenam Seo, et al.
Published: (2022-08-01)

Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia
by: Bo-Guen Kim, et al.
Published: (2023-05-01)

Comparison of Piperacillin and Tazobactam Pharmacokinetics in Critically Ill Patients with Trauma or with Burn
by: Daniel J. Selig, et al.
Published: (2022-05-01)

Simple HPLC-UV Method for Piperacillin/Tazobactam Assay in Human Plasma
by: Khaled Abdelkawy, et al.
Published: (2023-02-01)

The impact of a best practice advisory on inpatient prescribing of piperacillin-tazobactam
by: Katherine L. Peterson, et al.
Published: (2022-01-01)

Galactomannan detection from piperacillin-tazobactam brands available in the Brazilian market
by: Melissa Orzechowski Xavier, et al.

Impact on Bacterial Resistance of Therapeutically Nonequivalent Generics: The Case of Piperacillin-Tazobactam.
by: Carlos A Rodriguez, et al.
Published: (2016-01-01)

Bloodstream Infection due to Piperacillin/Tazobactam Non-Susceptible, Cephalosporin-Susceptible <i>Escherichia coli</i>: A Missed Opportunity for De-Escalation of Therapy
by: Leah Carlisle, et al.
Published: (2018-12-01)

Evaluation of Piperacillin/Sulbactam, Piperacillin/Tazobactam and Cefoperazone/Sulbactam Dosages in Gram-Negative Bacterial Bloodstream Infections by Monte Carlo Simulation
by: Xueting Wang, et al.
Published: (2023-02-01)

Analysis of IV Drugs in the Hospital Workflow by Raman Spectroscopy: The Case of Piperacillin and Tazobactam
by: Ioanna Chrisikou, et al.
Published: (2021-09-01)

A Case of DRESS Syndrome Associated with Piperacillin-Tazobactam Treatment and Literature Review
by: Seven ULUDOKUMACI, et al.
Published: (2012-12-01)

Acute kidney injury in villous cancer patients treated with vancomycin and tazobactam/piperacillin
by: Kaori Nakatani, et al.
Published: (2022-08-01)

Synthesis and evaluation of polymeric micelle containing piperacillin/tazobactam for enhanced antibacterial activity
by: Milani Morteza, et al.
Published: (2019-01-01)

Risk factors of nosocomial infections caused by piperacillin-tazobactam resistant Pseudomonas aeruginosa
by: Đorđević Zorana, et al.
Published: (2013-01-01)

Comparison of piperacillin plasma concentrations in a prospective randomised trial of extended infusion versus intermittent bolus of piperacillin/tazobactam in paediatric patients
by: Tatchanapong Chongcharoenyanon, et al.
Published: (2021-07-01)

Linear IgA dermatosis secondary to treatment with piperacillin-tazobactam in a nonagenarian patient
by: Vanesa García-Paz, et al.
Published: (2024-01-01)

Piperacillin–Tazobactam as an Adjuvant in the Mechanical Treatment of Patients with Periodontitis: A Randomized Clinical Study
by: Dolores Hurtado-Celotti, et al.
Published: (2022-11-01)

Electrolyte Disorders Associated with Piperacillin/Tazobactam: A Pharmacovigilance Study Using the FAERS Database
by: Heenam Seo, et al.
Published: (2023-01-01)

The effect of meropenem versus piperacillin-tazobactam in critically ill patients with sepsis and septic shock
by: Yang Sun, et al.
Published: (2023-06-01)

Cross-reactivity between piperacillin–tazobactam and cefoperazone–sulbactam in drug-induced immune thrombocytopenia
by: Xiaoyan He, et al.
Published: (2023-03-01)

Prevalence of Piperacillin-Tazobactam induced Hypersensitivity Reaction in Workers of Stallion’s Pharmaceutical Factory at Lahore
by: Anwar Ali Sulehri, et al.
Published: (2022-11-01)